Aytu Historical Balance Sheet

AYTU Stock

USD 1.62 0.02 1.25%

Trend analysis of Aytu BioScience balance sheet accounts such as Short Long Term Debt Total of 8.1 M, Other Current Liabilities of 49.9 M or Total Current Liabilities of 65.3 M provides information on Aytu BioScience's total assets, liabilities, and equity, which is the actual value of Aytu BioScience to its prevalent stockholders. By breaking down trends over time using Aytu BioScience balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Aytu BioScience latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aytu BioScience is a good buy for the upcoming year.

Aytu BioScience Inventory

6.65 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aytu BioScience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Aytu Stock please use our How to Invest in Aytu BioScience guide.

About Aytu Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Aytu BioScience at a specified time, usually calculated after every quarter, six months, or one year. Aytu BioScience Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aytu BioScience and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aytu currently owns. An asset can also be divided into two categories, current and non-current.

Aytu BioScience Balance Sheet Chart

At this time, Aytu BioScience's Property Plant And Equipment Gross is comparatively stable compared to the past year. Total Current Assets is likely to gain to about 65 M in 2024, whereas Property Plant And Equipment Net is likely to drop slightly above 1.4 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Aytu BioScience assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aytu BioScience books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Aytu BioScience balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aytu BioScience are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Aytu BioScience's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Aytu BioScience current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aytu BioScience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Aytu Stock please use our How to Invest in Aytu BioScience guide.At this time, Aytu BioScience's Property Plant And Equipment Gross is comparatively stable compared to the past year. Total Current Assets is likely to gain to about 65 M in 2024, whereas Property Plant And Equipment Net is likely to drop slightly above 1.4 M in 2024.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	18.2M	16.4M	15.1M	8.1M
Total Assets	137.6M	136.5M	118.1M	124.0M

Short Long Term Debt Total Total Assets

Aytu BioScience balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock Total Equity	Other Current Assets	Common Stock	Net Tangible Assets	Current Deferred Revenue	Non Currrent Assets Other	Retained Earnings Total Equity
Total Assets		0.79	0.57	0.94	0.92	0.86	-0.56	-0.72	0.97	0.91	0.97	0.91	0.47	0.76	0.86	0.95	0.91	0.98	0.67	-0.43	0.61	-0.43	-0.26	0.83	0.52	-0.8
Short Long Term Debt Total	0.79		0.36	0.74	0.75	0.78	-0.42	-0.58	0.83	0.74	0.83	0.74	0.22	0.57	0.68	0.73	0.76	0.74	0.69	-0.7	0.39	-0.7	-0.35	0.69	0.43	-0.79
Other Current Liab	0.57	0.36		0.7	0.23	0.45	0.0	-0.95	0.58	0.33	0.4	0.33	0.86	0.81	0.88	0.77	0.61	0.67	-0.04	-0.35	0.94	-0.35	-0.57	0.76	0.79	-0.66
Total Current Liabilities	0.94	0.74	0.7		0.76	0.88	-0.27	-0.83	0.91	0.73	0.89	0.73	0.64	0.74	0.91	0.98	0.97	0.94	0.65	-0.39	0.65	-0.39	-0.53	0.94	0.65	-0.74
Total Stockholder Equity	0.92	0.75	0.23	0.76		0.78	-0.74	-0.41	0.89	0.96	0.95	0.96	0.13	0.54	0.61	0.74	0.76	0.87	0.74	-0.35	0.36	-0.35	0.06	0.6	0.22	-0.64
Property Plant And Equipment Net	0.86	0.78	0.45	0.88	0.78		-0.21	-0.59	0.86	0.68	0.9	0.68	0.24	0.51	0.7	0.82	0.96	0.79	0.73	-0.3	0.45	-0.3	-0.5	0.9	0.3	-0.61
Net Debt	-0.56	-0.42	0.0	-0.27	-0.74	-0.21		0.13	-0.55	-0.83	-0.56	-0.83	0.07	-0.47	-0.3	-0.34	-0.19	-0.56	-0.27	0.3	-0.24	0.3	-0.56	-0.04	-0.01	0.51
Retained Earnings	-0.72	-0.58	-0.95	-0.83	-0.41	-0.59	0.13		-0.72	-0.5	-0.59	-0.5	-0.86	-0.9	-0.97	-0.89	-0.75	-0.8	-0.17	0.49	-0.88	0.49	0.61	-0.84	-0.83	0.83
Accounts Payable	0.97	0.83	0.58	0.91	0.89	0.86	-0.55	-0.72		0.91	0.96	0.91	0.42	0.75	0.84	0.92	0.88	0.96	0.61	-0.44	0.65	-0.44	-0.27	0.84	0.46	-0.8
Cash	0.91	0.74	0.33	0.73	0.96	0.68	-0.83	-0.5	0.91		0.92	1.0	0.21	0.68	0.67	0.76	0.69	0.9	0.6	-0.41	0.49	-0.41	0.11	0.57	0.3	-0.74
Non Current Assets Total	0.97	0.83	0.4	0.89	0.95	0.9	-0.56	-0.59	0.96	0.92		0.92	0.27	0.64	0.74	0.87	0.9	0.92	0.76	-0.39	0.47	-0.39	-0.22	0.79	0.35	-0.73
Cash And Short Term Investments	0.91	0.74	0.33	0.73	0.96	0.68	-0.83	-0.5	0.91	1.0	0.92		0.21	0.68	0.67	0.76	0.68	0.89	0.6	-0.42	0.49	-0.42	0.11	0.57	0.3	-0.74
Common Stock Shares Outstanding	0.47	0.22	0.86	0.64	0.13	0.24	0.07	-0.86	0.42	0.21	0.27	0.21		0.69	0.79	0.69	0.5	0.58	0.03	-0.28	0.7	-0.28	-0.54	0.6	0.9	-0.51
Non Current Liabilities Total	0.76	0.57	0.81	0.74	0.54	0.51	-0.47	-0.9	0.75	0.68	0.64	0.68	0.69		0.92	0.85	0.64	0.84	0.13	-0.5	0.87	-0.5	-0.33	0.67	0.69	-0.91
Other Stockholder Equity	0.86	0.68	0.88	0.91	0.61	0.7	-0.3	-0.97	0.84	0.67	0.74	0.67	0.79	0.92		0.96	0.84	0.91	0.34	-0.52	0.85	-0.52	-0.51	0.87	0.8	-0.88
Total Liab	0.95	0.73	0.77	0.98	0.74	0.82	-0.34	-0.89	0.92	0.76	0.87	0.76	0.69	0.85	0.96		0.93	0.96	0.54	-0.44	0.75	-0.45	-0.5	0.92	0.7	-0.83
Property Plant And Equipment Gross	0.91	0.76	0.61	0.97	0.76	0.96	-0.19	-0.75	0.88	0.69	0.9	0.68	0.5	0.64	0.84	0.93		0.87	0.7	-0.34	0.56	-0.34	-0.57	0.95	0.53	-0.69
Total Current Assets	0.98	0.74	0.67	0.94	0.87	0.79	-0.56	-0.8	0.96	0.9	0.92	0.89	0.58	0.84	0.91	0.96	0.87		0.56	-0.44	0.72	-0.44	-0.26	0.82	0.59	-0.82
Short Term Debt	0.67	0.69	-0.04	0.65	0.74	0.73	-0.27	-0.17	0.61	0.6	0.76	0.6	0.03	0.13	0.34	0.54	0.7	0.56		-0.3	-0.1	-0.3	-0.2	0.52	0.21	-0.3
Common Stock Total Equity	-0.43	-0.7	-0.35	-0.39	-0.35	-0.3	0.3	0.49	-0.44	-0.41	-0.39	-0.42	-0.28	-0.5	-0.52	-0.44	-0.34	-0.44	-0.3		-0.39	1.0	0.16	-0.32	-0.59	0.67
Other Current Assets	0.61	0.39	0.94	0.65	0.36	0.45	-0.24	-0.88	0.65	0.49	0.47	0.49	0.7	0.87	0.85	0.75	0.56	0.72	-0.1	-0.39		-0.39	-0.34	0.69	0.64	-0.72
Common Stock	-0.43	-0.7	-0.35	-0.39	-0.35	-0.3	0.3	0.49	-0.44	-0.41	-0.39	-0.42	-0.28	-0.5	-0.52	-0.45	-0.34	-0.44	-0.3	1.0	-0.39		0.16	-0.32	-0.6	0.67
Net Tangible Assets	-0.26	-0.35	-0.57	-0.53	0.06	-0.5	-0.56	0.61	-0.27	0.11	-0.22	0.11	-0.54	-0.33	-0.51	-0.5	-0.57	-0.26	-0.2	0.16	-0.34	0.16		-0.68	-0.48	0.34
Current Deferred Revenue	0.83	0.69	0.76	0.94	0.6	0.9	-0.04	-0.84	0.84	0.57	0.79	0.57	0.6	0.67	0.87	0.92	0.95	0.82	0.52	-0.32	0.69	-0.32	-0.68		0.59	-0.67
Non Currrent Assets Other	0.52	0.43	0.79	0.65	0.22	0.3	-0.01	-0.83	0.46	0.3	0.35	0.3	0.9	0.69	0.8	0.7	0.53	0.59	0.21	-0.59	0.64	-0.6	-0.48	0.59		-0.6
Retained Earnings Total Equity	-0.8	-0.79	-0.66	-0.74	-0.64	-0.61	0.51	0.83	-0.8	-0.74	-0.73	-0.74	-0.51	-0.91	-0.88	-0.83	-0.69	-0.82	-0.3	0.67	-0.72	0.67	0.34	-0.67	-0.6

Click cells to compare fundamentals

Aytu BioScience Account Relationship Matchups

Aytu BioScience balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	152.8M	265.7M	137.6M	136.5M	118.1M	124.0M
Other Current Liab	14.9M	7.4M	49.5M	55.5M	47.5M	49.9M
Total Current Liabilities	28.3M	109.4M	64.4M	69.0M	62.2M	65.3M
Total Stockholder Equity	95.0M	137.6M	46.1M	39.4M	27.7M	24.5M
Property Plant And Equipment Net	892.6K	8.7M	6.3M	3.9M	1.5M	1.4M
Net Debt	(46.1M)	(21.3M)	(1.2M)	(6.6M)	(4.9M)	(5.1M)
Retained Earnings	(120.0M)	(178.3M)	(288.5M)	(304.1M)	(320.0M)	(304.0M)
Accounts Payable	11.8M	19.3M	11.0M	13.5M	10.4M	5.4M
Cash	48.1M	49.6M	19.4M	23.0M	20.0M	12.0M
Non Current Assets Total	77.9M	160.4M	77.7M	63.6M	56.2M	31.3M
Cash And Short Term Investments	48.1M	49.6M	19.4M	23.0M	20.0M	12.1M
Common Stock Shares Outstanding	226.0K	837.3K	1.5M	3.3M	5.5M	5.8M
Liabilities And Stockholders Equity	152.8M	265.7M	137.6M	136.5M	118.1M	124.0M
Non Current Liabilities Total	29.5M	18.7M	27.1M	28.1M	28.2M	29.6M
Other Stockholder Equity	215.0M	315.9M	331.4M	343.5M	347.7M	365.1M
Total Liab	57.8M	128.1M	91.5M	97.1M	90.4M	94.9M
Property Plant And Equipment Gross	1.2M	8.7M	6.3M	3.9M	3.6M	3.8M
Total Current Assets	75.0M	105.2M	59.9M	72.8M	61.9M	65.0M
Common Stock Total Equity	179.0	1.8K	12.6K	3K	2.7K	2.6K
Other Current Assets	5.7M	1.0M	8.0M	8.9M	5.6M	5.9M
Common Stock	12.6K	3K	4K	1K	900.0	855.0
Net Tangible Assets	34.7M	(13.7M)	(24.5M)	(19.6M)	(17.7M)	(16.8M)
Non Currrent Assets Other	33.0K	465K	766K	792K	2.2M	2.3M
Intangible Assets	48.9M	85.5M	70.6M	59.0M	52.5M	35.8M
Property Plant Equipment	258.5K	8.7M	6.3M	3.9M	4.4M	4.7M
Other Liab	28.8M	15.9M	12.8M	13.4M	15.4M	12.2M
Other Assets	33.0K	465K	766K	792K	910.8K	956.3K
Net Receivables	5.2M	28.2M	21.7M	28.9M	23.6M	24.8M
Inventory	10.0M	16.3M	10.8M	12.0M	12.6M	6.6M
Non Current Liabilities Other	18.3M	15.9M	12.8M	7.0M	4.5M	4.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aytu Stock Analysis

When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aytu Historical Balance Sheet

Aytu BioScience Inventory

6.65 Million

About Aytu Balance Sheet Analysis

Aytu BioScience Balance Sheet Chart

Total Assets

Total Current Liabilities

Aytu BioScience balance sheet Correlations

Aytu BioScience Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aytu BioScience balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aytu Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.98	Total Assets
Total Liab	+ 0.98	Total Current Liabilities
Accounts Payable	+ 0.97	Total Assets
Non Current Assets Total	+ 0.97	Total Assets

Other Stockholder Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.95	Other Current Liab
Retained Earnings Total Equity	- 0.91	Non Current Liabilities Total
Non Current Liabilities Total	- 0.9	Retained Earnings
Total Liab	- 0.89	Retained Earnings
Retained Earnings Total Equity	- 0.88	Other Stockholder Equity